The reported statements, read against the company's own industry.
What stands out
Valued far above the size of its business
Financials view
Market Capitalization
2.45BCNY
365.30M · vs all stocks (USD)
Updated Sep 21, 2026
Revenue (TTM)
140.11MCNY
20.91M · vs all stocks (USD)
Updated Sep 21, 2026
Profit Margin
-29.01%
vs Scientific & Technical Instruments peers
Updated Sep 21, 2026
Beta
0.4700x
vs all stocks
Updated Sep 21, 2026
52-Week Change
-7.89%
vs all stocks
Updated Sep 21, 2026
Market Capitalization
2.45BCNY
365.30M · vs all stocks (USD)
Updated Sep 21, 2026
Enterprise Value
2.42BCNY
361.33M · vs all stocks (USD)
Updated Sep 21, 2026
Price to Sales (TTM)
17.47x
vs Scientific & Technical Instruments peers
Updated Sep 21, 2026
Price to Book (MRQ)
5.56x
vs Scientific & Technical Instruments peers
Updated Sep 21, 2026
Enterprise to Revenue
17.28x
vs Scientific & Technical Instruments peers
Updated Sep 21, 2026
Enterprise to EBITDA
-158.79x
vs Scientific & Technical Instruments peers
Updated Sep 21, 2026
Gross Margin
24.30%
vs Scientific & Technical Instruments peers
Provider-reported. Gross Profit (TTM) ÷ Revenue (TTM) on this page gives 33.86%.Updated Sep 21, 2026
Profit Margin
-29.01%
vs Scientific & Technical Instruments peers
Updated Sep 21, 2026
Operating Margin
-17.96%
vs Scientific & Technical Instruments peers
Updated Sep 21, 2026
Return on Assets (TTM)
-2.56%
vs Scientific & Technical Instruments peers
Updated Sep 21, 2026
Return on Equity (TTM)
-8.81%
vs Scientific & Technical Instruments peers
Updated Sep 21, 2026
Revenue (TTM)
140.11MCNY
20.91M · vs all stocks (USD)
Updated Sep 21, 2026
Revenue per Share (TTM)
2.11CNYUpdated Sep 21, 2026
Quarterly Revenue Growth
-12.70%
vs Scientific & Technical Instruments peers
Updated Sep 21, 2026
Gross Profit (TTM)
47.44MCNY
7.08M · vs all stocks (USD)
Updated Sep 21, 2026
EBITDA (TTM)
-15.25MCNY
-2.28M · vs all stocks (USD)
Updated Sep 21, 2026
Net Income (TTM)
-40.65MCNY
-6.07M · vs all stocks (USD)
Updated Sep 21, 2026
Quarterly Earnings Growth (YoY)
-3.15%
vs Scientific & Technical Instruments peers
Updated Sep 21, 2026
Operating Cash Flow (TTM)
20.34MCNY
3.03M · vs all stocks (USD)
Updated Sep 21, 2026
Levered Free Cash Flow (TTM)
25.86MCNY
3.86M · vs all stocks (USD)
Updated Sep 21, 2026
Payout Ratio
0.00%
vs Scientific & Technical Instruments peers
Updated Sep 21, 2026
Minority Interest (Equity)
-1.27MCNYFY2025 · Dec 31, 2025
Revenue
160.18MCNYFY2025 · Dec 31, 2025
Cost of Goods Sold
94.31MCNYFY2025 · Dec 31, 2025
Gross Profit
65.86MCNYFY2025 · Dec 31, 2025
Operating Income
-23.87MCNY
-3.56M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
-17.60MCNYFY2025 · Dec 31, 2025
Income Tax Expense
10.43MCNYFY2025 · Dec 31, 2025
Net Income
-28.03MCNYFY2025 · Dec 31, 2025
EBIT
-15.59MCNYFY2025 · Dec 31, 2025
EBITDA (Income Statement)
-9.12MCNYFY2025 · Dec 31, 2025
Research & Development
40.45MCNYFY2025 · Dec 31, 2025
Selling, General & Administrative
16.97MCNYFY2025 · Dec 31, 2025
Other Operating Expenses
2.64MCNYFY2025 · Dec 31, 2025
Non-operating Interest Income
279.07KCNYFY2025 · Dec 31, 2025
Non-operating Interest Expense
2.01MCNYFY2025 · Dec 31, 2025
EPS (Basic)
-0.4100CNYFY2025 · Dec 31, 2025
EPS (Diluted)
-0.4100CNYFY2025 · Dec 31, 2025
Basic Shares Outstanding
68.12MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
68.12MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
-28.03MCNYFY2025 · Dec 31, 2025
Minority Interests (P&L)
99.67KCNYFY2025 · Dec 31, 2025
Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025
Operating Cash Flow
97.64MCNYFY2025 · Dec 31, 2025
Free Cash Flow
96.78MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
83.71MCNYFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
-28.03MCNYFY2025 · Dec 31, 2025
Other Non-cash Items
3.11MCNYFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
81.07MCNYFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
41.49MCNYFY2025 · Dec 31, 2025
Capital Expenditures
-860.81KCNYFY2025 · Dec 31, 2025
Purchase of Investments
-65.00MCNYFY2025 · Dec 31, 2025
Sale of Investments
66.02MCNYFY2025 · Dec 31, 2025
Other Investing Activity
-6.75MCNYFY2025 · Dec 31, 2025
Net Investing Cash Flow
-6.59MCNYFY2025 · Dec 31, 2025
Long-term Debt Issuance
35.00MCNYFY2025 · Dec 31, 2025
Long-term Debt Payments
-51.00MCNYFY2025 · Dec 31, 2025
Common Dividends Paid
-1.64MCNYFY2025 · Dec 31, 2025
Other Financing Charges
4.73MCNYFY2025 · Dec 31, 2025
Net Financing Cash Flow
-12.91MCNYFY2025 · Dec 31, 2025
Shares Outstanding
68.04MSharesUpdated Sep 21, 2026
Float Shares
39.02MSharesUpdated Sep 21, 2026
% Held by Insiders
57.90%
vs all stocks
Updated Sep 21, 2026
% Held by Institutions
1.59%
vs all stocks
Updated Sep 21, 2026
Total Cash (MRQ)
72.53MCNY
10.82M · vs all stocks (USD)
Updated Sep 21, 2026
Total Cash per Share (MRQ)
1.07CNYUpdated Sep 21, 2026
Total Debt (MRQ)
47.23MCNY
7.05M · vs all stocks (USD)
Updated Sep 21, 2026
Total Debt to Equity (MRQ)
0.1076x
vs Scientific & Technical Instruments peers
Updated Sep 21, 2026
Current Ratio (MRQ)
2.67x
vs Scientific & Technical Instruments peers
Updated Sep 21, 2026
Book Value per Share (MRQ)
6.47CNYUpdated Sep 21, 2026
Total Assets
601.80MCNY
89.80M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
340.01MCNYFY2025 · Dec 31, 2025
Total Liabilities
145.74MCNYFY2025 · Dec 31, 2025
Total Non-current Assets
261.80MCNYFY2025 · Dec 31, 2025
Total Non-current Liabilities
1.85MCNYFY2025 · Dec 31, 2025
Total Current Liabilities
143.90MCNYFY2025 · Dec 31, 2025
Cash
90.46MCNYFY2025 · Dec 31, 2025
Cash Equivalents
4.17MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents
94.62MCNYFY2025 · Dec 31, 2025
Accounts Receivable
160.70MCNYFY2025 · Dec 31, 2025
Inventory
56.52MCNYFY2025 · Dec 31, 2025
Accounts Payable
53.60MCNYFY2025 · Dec 31, 2025
Short-term Debt
59.75MCNYFY2025 · Dec 31, 2025
Other Current Liabilities
1.73MCNYFY2025 · Dec 31, 2025
Long-term Debt
1.08MCNYFY2025 · Dec 31, 2025
Other Non-current Liabilities
766.52KCNYFY2025 · Dec 31, 2025
Common Stock (Book)
68.04MCNYFY2025 · Dec 31, 2025
Retained Earnings
975.80KCNYFY2025 · Dec 31, 2025
Total Shareholders' Equity
456.06MCNY
68.05M · vs all stocks (USD)
FY2025 · Dec 31, 2025
52-Week Low
30.68CNYUpdated Sep 21, 2026
52-Week High
67.22CNYUpdated Sep 21, 2026
52-Week Change
-7.89%
vs all stocks
Updated Sep 21, 2026
Beta
0.4700x
vs all stocks
Updated Sep 21, 2026
50-Day MA
36.56CNYUpdated Sep 21, 2026
200-Day MA
47.34CNYUpdated Sep 21, 2026
Avg 10-Day Volume
903.28KSharesUpdated Sep 21, 2026
Avg 30-Day Volume
1.05MSharesUpdated Sep 21, 2026
Diluted EPS (TTM)
-0.6000CNYUpdated Sep 21, 2026
2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Valued far above the size of its businessSignificant